Arima Genomics, Inc., a San Diego, CA-based company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and disease, completed its Series A round of financing.
The amount of the deal was not disclosed.
The round was led by Agilent Technologies, Inc. (NYSE: A) and Cowin Venture, joined by Vectr Ventures and Berkeley Catalyst Fund.
The company intends to use the funds to go toward expanding its commercial efforts, driving the development of new applications to the existing platform including adding structural analysis capabilities to conventional chromatin immunoprecipitation via HiChIP, and building new products including smooth-coverage HiC for applications in gap-less de novo assemblies and population sequencing. The funding will also support scaling of Arima’s operations and enhancing customer service and support experience.
Led by Siddarth Selvaraj, CEO and Co-founder, Arima Genomics is a biotechnology company that aims to accelerate the understanding of genome sequence and structure.
FinSMEs
24/02/2020